TIVCNCMHealthcare·Medical Devices#134 in industry

Tivic Health Systems, Inc.

+9.4% · 90d

$1.40

+0.07 (+5.26%)

After-Hours $1.39(-0.01)

News

(1)

April 2026

Apr 20, 20261 week agoPRE 14AHealthcare

Tivic (TIVC) seeks votes on major financing deals and equity conversions

TIVCTivic Health Systems, Inc.

# 📰 Preliminary Proxy Statement Overview 📜 This document is a preliminary proxy statement (PRE 14A), which means Tivic Health Systems, Inc. (TIVC) is providing detailed information to its stockholders ahead of the 2026 Annual Meeting of Stockholders. Essentially, it's an instruction manual detaili

Read summaryView on SEC EDGAR

Key Data

Market Cap$4.0M

Open$1.30

Prev Close$1.33

Day Range$1.23 – $1.40

52W Range$0.72 – $6.95

Volume263,294

P/E (TTM)—

EPS$-6.92

Dividend Yield—

Beta1.84

About

Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in Fremont, California.

Healthcare · Medical Devices

52 employees

tivichealth.com